

## Reviews in Cardiovascular Medicine Author Index to Volume 3

### **Aghababian, Richard V.**

Acutely decompensated heart failure: opportunities to improve care and outcomes in the emergency department. 3(suppl 4):S3-S9.

### **Ansel, Gary M.**

Use of glycoprotein IIb/IIIa platelet inhibitors in peripheral vascular interventions. 3(suppl 1):S35-S40.

### **Botti, Charles F.**

*See Ansel, Gary M.*

### **Cesario, David A.**

Beta-blocker therapy for heart failure: the standard of care. 3(1):14-21.

### **Creager, Mark A.**

Eplerenone and enalapril therapy. In: Best of the ACC Scientific Session 2002 [Meeting Review]. 3(2):85-104.

Immediate repair versus surveillance of small abdominal aortic aneurysms [Literature Review]. 3(4):203-205.

Symposium: peripheral arterial disease: new therapeutic strategies. In: Best of the AHA Scientific Sessions 2001 [Meeting Review]. 3(1):22-48.

### **de Feyter, Pim J.**

*See Nieman, Koen*

### **Dippel, Eric J.**

Practical issues of platelet glycoprotein IIb/IIIa receptor inhibition: saving lives and saving money. 3(suppl 1):S28-S34.

### **Drachman, Douglas E.**

Clinical experience with drug-eluting stents. 3(suppl 5):S31-S37.

### **Eigler, Neal L.**

*See McClean, Dougal R.*

### **Emerman, Charles L.**

Safety and efficacy of nesiritide for the treat-

ment of decompensated heart failure. 3(suppl 4):S28-S34.

### **Fasseas, Panayotis**

Unprotected left main percutaneous coronary intervention [Literature Review]. 3(3):157-160.

### **Faxon, David P.**

Gene therapy shows efficacy and continued safety. In: Best of the AHA Scientific Sessions 2001 [Meeting Review]. 3(1):22-48.

Late-breaking trial results presented in Stockholm [Meeting Review]. 3(2):105-106.

Percutaneous coronary intervention. In: Best of the ACC Scientific Session 2002 [Meeting Review]. 3(2):85-104.

Revascularization in diabetes: have stents made a difference? [Literature Review]. 3(1):60-62.

*See French, Matthew H.*

### **Fonarow, Gregg C.**

Angiotensin receptor antagonist therapy fails to reduce heart failure mortality [Literature Review]. 3(3):162-163.

Heart failure. In: Best of the ACC Scientific Session 2002 [Meeting Review]. 3(2):85-104.

Heart failure. In: Best of the AHA Scientific Sessions 2001 [Meeting Review]. 3(1):22-48.

Pharmacologic therapies for acutely decompensated heart failure. 3(suppl 4):S18-S27.

Role of in-hospital initiation of cardioprotective therapies to improve treatment rates and clinical outcomes. 3(suppl 3):S2-S10.

*See Cesario, David A.*

### **Fowler, Michael**

Beta-adrenergic blocking drugs in severe heart failure. 3(suppl 3):S20-S26.

### **French, Matthew H.**

Current anticoagulation options in percuta-

neous intervention: designing patient-specific strategies. 3(4):176-182.

Update on radiation for restenosis. 3(1):1-6.

### **Gattis, Wendy A.**

Initiation management predischARGE process for assessment of carvedilol therapy for heart failure (IMPACT-HF) study: design and implications. 3(suppl 3):S48-S54.

*See GheorghiadE, Mihai*

### **George, Barry S.**

*See Ansel, Gary M.*

### **Gersh, Bernard J.**

AMISTAD II trial. In: Best of the ACC Scientific Session 2002 [Meeting Review]. 3(2):85-104.

Randomized trials of treatment for chronic stable angina [Meeting Review]. 3(3):145-147.

Results of the ASSENT-3 trial [Literature Review]. 3(2):111-115.

### **GheorghiadE, Mihai**

*See Gattis, Wendy A.*

Treatment gaps in the pharmacologic management of heart failure. 3(suppl 3):S11-S19.

### **Gilbert, Edward M.**

Cost-effectiveness of beta-blocker treatment in heart failure. 3(suppl 3):S42-S47.

### **Gross, Stacey B.**

CT imaging of coronary arteries and the late-breaking trials. In: Best of the AHA Scientific Sessions 2001 [Meeting Review]. 3(1):22-48.

### **Grossman, Jessica D.**

Angiogenesis. 3(3):138-144.

### **Grossman, William**

*See Grossman, Jessica D.*

### **Hachamovitch, Rory**

Nuclear cardiology. In: Best of the AHA

- Scientific Sessions 2001 [Meeting Review]. 3(1):22-48.  
*See Thomson, Louise E.J.*
- Henry, Timothy D.**  
*See Schwartz, Robert S.*
- Herrington, David M.**  
 Effects of estrogen on thrombosis and inflammation. [Meeting Review]. 3(1):49-56.
- Holmes, David R.**  
 Percutaneous coronary intervention. In: Best of the ACC Scientific Session 2002 [Meeting Review]. 3(2):85-104.  
*See Fasseas, Panayotis*  
*See Orford, James L.*
- Jacobs, Alice K.**  
 Acute coronary syndromes. In: Best of the ACC Scientific Session 2002 [Meeting Review]. 3(2):85-104.  
 Canadian Antioxidant Restenosis Trial (CART-1). In: Best of the AHA Scientific Sessions 2001 [Meeting Review]. 3(1):22-48.  
 Coronary stents. In: Best of the ACC Scientific Session 2002 [Meeting Review]. 3(2):85-104.
- Keane, David**  
 Pulmonary vein isolation for atrial fibrillation. 3(4):167-175.
- Kereiakes, Dean**  
*See Lepor, Norman E.*
- Kirk, J. Douglas**  
*See Panacek, Edward A.*
- Kumar, Kavita**  
 Unusual presentation of an acute inferior myocardial infarction. 3(3):152-156.
- Lepor, Norman E.**  
 Antioxidants as adjuvant therapy for cardiovascular disease [Literature Review]. 3(2):117-119.  
 Choices for stroke prevention [Literature Review]. 3(4):202-203.  
 CT imaging of coronary arteries and the late-breaking trials. In: Best of the AHA Scientific Sessions 2001 [Meeting Review]. 3(1):22-48.  
 Doppler imaging to predict beta-blocker performance [Literature Review]. 3(4):206-207.  
 Drugs and lipid metabolism. In: Best of the AHA Scientific Sessions 2001 [Meeting Review]. 3(1):22-48.  
 Effective and efficient strategies for coronary revascularization in the drug-eluting stent era. 3(suppl 5):S38-S50.  
 Prevention with statin and niacin [Literature Review]. 3(4):205-206.  
 Risk associated with "normal" blood pressure [Literature Review]. 3(3):161-162.  
*See Kumar, Kavita*  
 Symposium review: enter the drug-eluting stent revolution: a critical appraisal. In: Best of the ACC Scientific Session 2002 [Meeting Review]. 3(2):85-104.
- Triglycerides and coronary atherosclerosis: implications for treatments of mixed dyslipidemias [Literature Review]. 3(1):63-66.  
 Use of glycoprotein IIb/IIIa receptor inhibitors in acute coronary syndromes. 3(suppl 1):S3-S12.
- Lincoff, A. Michael**  
 Targeting the use of platelet IIb/IIIa inhibitors: treatment of acute myocardial infarction. 3(suppl 1):S13-S19.
- Madyoon, Hooman**  
*See Lepor, Norman E.*
- Maisel, Alan**  
 B-type natriuretic peptide measurements in diagnosing congestive heart failure in the dyspneic emergency department patient. 3(suppl 4):S10-S17.
- McCullough, Peter A.**  
 BNP multinational study. In: Best of the ACC Scientific Session 2002 [Meeting Review]. 3(2):85-104.  
 Cardiorenal risk: an important clinical intersection. 3(2):71-76.  
 Cardiorenal update. In: Best of the AHA Scientific Sessions 2001 [Meeting Review]. 3(1):22-48.  
*See Safley, David M.*  
 Update from the International Society on Hypertension in Blacks [Meeting Review]. 3(4):192-195.
- McClean, Douglas R.**  
 Stent design: implications for restenosis. 3(suppl 5):S16-S22.
- Meier-Ewert, Hans K.**  
 Targeting the use of glycoprotein IIb/IIIa antagonists—the diabetic patient. 3(suppl 1):S20-S27.
- Mixon, Timothy A.**  
 Single coronary artery with an ectopic origin and interarterial course: a case report and review of the literature. 3(2):107-110.
- Naqvi, Tasneem Z.**  
 Echocardiography. In: Best of the AHA Scientific Sessions 2001 [Meeting Review]. 3(1):22-48.  
*See Kumar, Kavita*
- Nesto, Richard W.**  
 Diabetes. In: Best of the AHA Scientific Sessions 2001 [Meeting Review]. 3(1):22-48.  
*See Meier-Ewert, Hans K.*  
 Stress perfusion nuclear imaging in diabetes [Literature Review]. 3(3):164-165.
- Nieman, Koen**  
 Noninvasive coronary imaging in the new millennium: a comparison of computed tomography and magnetic resonance techniques. 3(2):77-84.
- O'Connor, Christopher M.**  
*See Gattis, Wendy A.*  
*See Gheorghiade, Mihai*
- Orford, James L.**  
 Abciximab readministration. 3(2):67-70.
- Panacek, Edward A.**  
 Role of noninvasive ventilation in the management of acutely decompensated heart failure. 3(suppl 4):S35-S40.
- Pandian, Natesa G.**  
 Doppler hemodynamics. 3(1):57-59.
- Pattynama, Peter M.T.**  
*See Nieman, Koen*
- Peacock, W. Frank**  
 Rapid optimization: strategies for optimal care of decompensated congestive heart-failure patients in the emergency department. 3(suppl 4):S41-S48.
- Potvin Klein, Karen**  
*See Herrington, David M.*
- Price, Matthew J.**  
 New strategies in managing and preventing atherosclerosis: focus on HDL. 3(3):129-137.
- Prystowsky, Eric N.**  
 Cardiac resynchronization therapy for congestive heart failure [Literature Review]. 3(3):165-166.  
 Electrophysiology. In: Best of the ACC Scientific Session 2002 [Meeting Review]. 3(2):85-104.  
 Electrophysiology. In: Best of the AHA Scientific Sessions 2001 [Meeting Review]. 3(1):22-48.
- Rogers, Campbell D.K.**  
 Drug-eluting stents: role of stent design, delivery vehicle, and drug selection. 3(suppl 5):S10-S15.
- Ruskin, Jeremy**  
*See Keane, David*
- Safley, David M.**  
 Antiphospholipid syndrome with renal artery embolism: case report. 3(4):196-201.
- Schwartz, Robert S.**  
 Pathophysiology of coronary artery restenosis. 3(suppl 5):S4-S9.
- Scott, Nandita S.**  
 Mitral valve replacement for restenosis after repeat percutaneous mitral valvuloplasty. 3(3):148-151.
- Shah, Prediman K.**  
 Canadian Antioxidant Restenosis Trial (CART-1). In: Best of the AHA Scientific Sessions 2001 [Meeting Review]. 3(1):22-48.  
 Gene therapy shows efficacy and continued safety. In: Best of the AHA Scientific Sessions 2001 [Meeting Review]. 3(1):22-48.  
*See Price, Matthew J.*
- Silver, Mitchell J.**  
*See Ansel, Gary M.*
- Thomson, Louise E.J.**  
 Coronary artery calcium scoring using electron-beam computed tomography: where does this test fit into a clinical practice? 3(3):121-128.
- van Geuns, Robert-Jan M.**  
*See Nieman, Koen*

**Vogel, Robert A.**

Alcohol, heart disease, and mortality: a review. 3(1):7–13.

CT imaging of coronary arteries and the late-breaking trials. In: Best of the AHA Scientific Sessions 2001 [Meeting Review]. 3(1):22–48.

Percutaneous coronary intervention. In: Best of the ACC Scientific Session 2002 [Meeting Review]. 3(2):85–104.

WIZARD and AZACS trials. In: Best of the ACC Scientific Session 2002 [Meeting Review]. 3(2):85–104.

**Waksman, Ron**

Vascular brachytherapy: applications in the era of drug-eluting stents. 3(suppl 5):S23–S30.

**Watson, Linley E.**

*See* *Mixon, Timothy A.*

**Weber, Michael A.**

LIFE study. In: Best of the ACC Scientific

Session 2002 [Meeting Review]. 3(2):85–104.

The angiotensin II receptor blockers: opportunities across the spectrum of cardiovascular disease. 3(4):183–191.

**Weyman, Arthur E.**

Assessing the performance of hand-carried electrocardiographic devices [Literature Review]. 3(2):116–117.

Exploring the relationship between hyperlipidemia and aortic stenosis [Literature Review]. 3(3):160–161.

Patent foramen ovale. In: Best of the ACC Scientific Session 2002 [Meeting Review]. 3(2):85–104.

*See* *Scott, Nandita S.*

Which is the better method for assessing changes on doppler echocardiograms? [Literature Review]. 3(2):117.

**Wielopolski, Piotr**

*See* *Nieman, Koen*

**Yancy, Clyde W.**

Special clinical considerations of beta-blocker treatment. 3(suppl 3):S27–S35.

**Yeung, Alan C.**

Folate treatment to prevent nitrate tolerance [Literature Review]. 3(1):62–63.

Gene therapy shows efficacy and continued safety. In: Best of the AHA Scientific Sessions 2001 [Meeting Review]. 3(1):22–48.

Randomized comparison of the MULTI-LINK stent with or without adjunctive directional coronary atherectomy in coronary artery lesion: the AMIGO trial. In: Best of the ACC Scientific Session 2002 [Meeting Review]. 3(2):85–104.

**Young, James B.**

Hospital-based systems to improve quality of care for heart-failure patients. 3(suppl 3):S36–S41.

## *Reviews in Cardiovascular Medicine* Subject Index to Volume 3

### **Abciximab**

Dippel EJ. Practical issues of platelet glycoprotein IIb/IIIa receptor inhibition: saving lives and saving money. 3(suppl 1):S28–S34.

Lepor NE. Use of glycoprotein IIb/IIIa receptor inhibitors in acute coronary syndromes. 3(suppl 1):S3–S12.

Meier-Ewert HK, Nesto RW. Targeting the use of glycoprotein IIb/IIIa antagonists—the diabetic patient. 3(suppl 1):S20–S27.

Orford JL, Holmes DR. Abciximab readministration. 3(2):67–70.

### **Acute coronary syndrome**

Best of the ACC Scientific Session 2002 [Meeting Review]. 3(2):85–104.

Lepor NE. Use of glycoprotein IIb/IIIa receptor inhibitors in acute coronary syndromes. 3(suppl 1):S3–S12.

### **Adenosine**

Best of the ACC Scientific Session 2002 [Meeting Review]. 3(2):85–104.

### **AFFIRM trial**

Best of the ACC Scientific Session 2002 [Meeting Review]. 3(2):85–104.

### **African Americans**

McCullough PA. Update from the International Society on Hypertension in Blacks [Meeting Review]. 3(4):192–195.

Yancy CW. Special clinical considerations of beta-blocker treatment. 3(suppl 3):S27–S35.

### **Alcohol**

Vogel RA. Alcohol, heart disease, and mortality: a review. 3(1):7–13.

### **Aldosterone**

Best of the ACC Scientific Session 2002 [Meeting Review]. 3(2):85–104.

### **Aldosterone receptor blockers**

McCullough PA. Update from the International Society on Hypertension in Blacks [Meeting Review]. 3(4):192–195.

### **ALIVE trial**

Best of the AHA Scientific Sessions 2001 [Meeting Review]. 3(1):22–48.

### **AMIGO**

Best of the ACC Scientific Session 2002 [Meeting Review]. 3(2):85–104.

### **AMISTAD II**

Best of the ACC Scientific Session 2002 [Meeting Review]. 3(2):85–104.

### **Angina**

Yeung AC. Folate treatment to prevent nitrate tolerance [Literature Review]. 3(1):62–63.

### **Angina pectoris**

Gersh BJ. Randomized trials of treatment for chronic stable angina [Meeting Review]. 3(3):145–147.

### **Angiogenesis**

Grossman JD, Grossman W. Angiogenesis. 3(3):138–144.

### **Angiogenesis, myocardial**

Grossman JD, Grossman W. Angiogenesis. 3(3):138–144.

### **Angiography**

Nieman K, van Geuns R-JM, Wielopolski P, et al. Noninvasive coronary imaging in the new millennium: a comparison of computed tomography and magnetic resonance techniques. 3(2):77–84.

### **Angiography, noninvasive**

Best of the AHA Scientific Sessions 2001 [Meeting Review]. 3(1):22–48.

### **Angioplasty**

Ansel GM, George BS, Botti CF, Silver MJ. Use of glycoprotein IIb/IIIa platelet inhibitors in peripheral vascular interventions. 3(suppl 1):S35–S40.

Lepor NE, Madyoon H, Kereiakes D. Effective and efficient strategies for coronary revascularization in the drug-eluting stent era. 3(suppl 5):S38–S50.

### **Angiotensin**

Aghababian RV. Acutely decompensated heart failure: opportunities to improve care and outcomes in the emergency department. 3(suppl 4):S3–S9.

### **Angiotensin-converting enzyme inhibitors**

Fonarow GC. Angiotensin receptor antagonist therapy fails to reduce heart failure mortality [Literature Review]. 3(3):162–163.

Gheorghide M, Gattis WA, O'Connor CM. Treatment gaps in the pharmacologic management of heart failure. 3(suppl 3):S11–S19.

Weber MA. The angiotensin II receptor blockers: opportunities across the spectrum of cardiovascular disease. 3(4):183–191.

Young JB. Hospital-based systems to

- improve quality of care for heart-failure patients. 3(suppl 3):S36–S41.
- Angiotensin receptor antagonist**  
Fonarow GC. Angiotensin receptor antagonist therapy fails to reduce heart failure mortality [Literature Review]. 3(3):162–163.
- Angiotensin II receptor blockers**  
McCullough PA. Update from the International Society on Hypertension in Blacks [Meeting Review]. 3(4):192–195.  
Weber MA. The angiotensin II receptor blockers: opportunities across the spectrum of cardiovascular disease. 3(4):183–191.
- Anticoagulants**  
French MH, Faxon DP. Current anticoagulation options in percutaneous intervention: designing patient-specific strategies. 3(4):176–182.
- Antioxidants**  
Best of the AHA Scientific Sessions 2001 [Meeting Review]. 3(1):22–48.  
Lepor NE. Antioxidants as adjuvant therapy for cardiovascular disease [Literature Review]. 3(2):117–119.
- Antiphospholipid syndrome**  
Safley DM, McCullough PA. Antiphospholipid syndrome with renal artery embolism: case report. 3(4):196–201.
- Antiplatelet**  
Ansel GM, George BS, Botti CF, Silver MJ. Use of glycoprotein IIb/IIIa platelet inhibitors in peripheral vascular interventions. 3(suppl 1):S35–S40.  
Dippel EJ. Practical issues of platelet glycoprotein IIb/IIIa receptor inhibition: saving lives and saving money. 3(suppl 1):S28–S34.
- Aortic aneurysms**  
Creager MA. Immediate repair versus surveillance of small abdominal aortic aneurysms [Literature Review]. 3(4):203–205.
- Aortic stenosis**  
Weyman AE. Exploring the relationship between hyperlipidemia and aortic stenosis [Literature Review]. 3(3):160–161.
- Arrhythmia**  
Keane D, Ruskin J. Pulmonary vein isolation for atrial fibrillation. 3(4):167–175.
- Arrhythmia disorders, heritable**  
Best of the AHA Scientific Sessions 2001 [Meeting Review]. 3(1):22–48.
- Arterial thrombosis**  
Herrington DM, Potvin Klein K. Effects of estrogen on thrombosis and inflammation. [Meeting Review]. 3(1):49–56.
- Arteriosclerosis**  
Meier-Ewert HK, Nesto RW. Targeting the use of glycoprotein IIb/IIIa antagonists—the diabetic patient. 3(suppl 1):S20–S27.
- ASSENT-3**  
Gersh BJ. Results of the ASSENT-3 trial [Literature Review]. 3(2):111–115.
- Atenolol**  
Best of the ACC Scientific Session 2002 [Meeting Review]. 3(2):85–104.
- Atherosclerosis**  
Best of the ACC Scientific Session 2002 [Meeting Review]. 3(2):85–104.  
Lepor NE. Triglycerides and coronary atherosclerosis: implications for treatment of mixed dyslipidemias [Literature Review]. 3(1):63–66.  
McCullough PA. Cardiorenal risk: an important clinical intersection. 3(2):71–76.  
McCullough PA. Update from the International Society on Hypertension in Blacks [Meeting Review]. 3(4):192–195.  
Price MJ, Shah PK. New strategies in managing and preventing atherosclerosis: focus on HDL. 3(3):129–137.  
Vogel RA. Alcohol, heart disease, and mortality: a review. 3(1):7–13.  
Weyman AE. Exploring the relationship between hyperlipidemia and aortic stenosis [Literature Review]. 3(3):160–161.
- Atherosclerotic plaque**  
Rogers CDK. Drug-eluting stents: role of stent design, delivery vehicle, and drug selection. 3(suppl 5):S10–S15.
- Atrial fibrillation**  
Keane D, Ruskin J. Pulmonary vein isolation for atrial fibrillation. 3(4):167–175.
- Atrial septal defect**  
Scott NS, Weyman AE. Mitral valve replacement for stenosis after repeat percutaneous mitral valvuloplasty. 3(3):148–151.
- AZACS**  
Best of the ACC Scientific Session 2002 [Meeting Review]. 3(2):85–104.
- Azithromycin**  
Best of the ACC Scientific Session 2002 [Meeting Review]. 3(2):85–104.
- B-type natriuretic peptide**  
Best of the ACC Scientific Session 2002 [Meeting Review]. 3(2):85–104.  
Emerman CL. Safety and efficacy of nesiritide for the treatment of decompensated heart failure. 3(suppl 4):S28–S34.  
Peacock WF. Rapid optimization: strategies for optimal care of decompensated congestive heart-failure patients in the emergency department. 3(suppl 4):S41–S48.
- Beta-adrenergic blocking drugs**  
Fowler M. Beta-adrenergic blocking drugs in severe heart failure. 3(suppl 3):S20–S26.
- Beta<sub>1</sub>-adrenoreceptor selective agents**  
Cesario DA, Fonarow GC. Beta-blocker therapy for heart failure: the standard of care. 3(1):14–21.
- Beta-blockers**  
Cesario DA, Fonarow GC. Beta-blocker therapy for heart failure: the standard of care. 3(1):14–21.  
Fonarow GC. Role of in-hospital initiation of cardioprotective therapies to improve treatment rates and clinical outcomes. 3(suppl 3):S2–S10.  
Gersh BJ. Randomized trials of treatment for chronic stable angina [Meeting Review]. 3(3):145–147.  
Gheorghiade M, Gattis WA, O'Connor CM. Treatment gaps in the pharmacologic management of heart failure. 3(suppl 3):S11–S19.  
Gilbert EM. Cost-effectiveness of beta-blocker treatment in heart failure. 3(suppl 3):S42–S47.  
Yancy CW. Special clinical considerations of beta-blocker treatment. 3(suppl 3):S27–S35.  
Young JB. Hospital-based systems to improve quality of care for heart-failure patients. 3(suppl 3):S36–S41.
- Beta-blocker therapy**  
Gattis WA, O'Connor CM, Gheorghiade M. Initiation management predischARGE process for assessment of carvedilol therapy for heart failure (IMPACT-HF) study: design and implications. 3(suppl 3):S48–S54.
- Brachytherapy**  
French MH, Faxon DP. Update on radiation for restenosis. 3(1):1–6.
- Calcium channel blockers**  
Gersh BJ. Randomized trials of treatment for chronic stable angina [Meeting Review]. 3(3):145–147.
- Calcium deposition**  
Thomson LEJ, Hachamovitch R. Coronary artery calcium scoring using electron-beam computed tomography: where does this test fit into a clinical practice? 3(3):121–128.
- Cardiac pressures**  
Pandian NG. Doppler hemodynamics. 3(1):57–59.
- Cardiac resynchronization therapy**  
Best of the AHA Scientific Sessions 2001 [Meeting Review]. 3(1):22–48.  
Prystowsky EN. Cardiac resynchronization therapy for congestive heart failure [Literature Review]. 3(3):165–166.
- Cardioprotection**  
Vogel RA. Alcohol, heart disease, and mortality: a review. 3(1):7–13.
- Cardiovascular disease**  
Best of the AHA Scientific Sessions 2001 [Meeting Review]. 3(1):22–48.

- McCullough PA. Cardiorenal risk: an important clinical intersection. 3(2):71–76.
- McCullough PA. Update from the International Society on Hypertension in Blacks [Meeting Review]. 3(4):192–195.
- Carvedilol**  
Best of the AHA Scientific Sessions 2001 [Meeting Review]. 3(1):22–48.
- Catheter ablation**  
Keane D, Ruskin J. Pulmonary vein isolation for atrial fibrillation. 3(4):167–175.
- Cholesterol**  
Price MJ, Shah PK. New strategies in managing and preventing atherosclerosis: focus on HDL. 3(3):129–137.
- Cholesterol transfer protein**  
Best of the AHA Scientific Sessions 2001 [Meeting Review]. 3(1):22–48.
- Chronic kidney disease**  
Best of the AHA Scientific Sessions 2001 [Meeting Review]. 3(1):22–48.  
McCullough PA. Cardiorenal risk: an important clinical intersection. 3(2):71–76.  
McCullough PA. Update from the International Society on Hypertension in Blacks [Meeting Review]. 3(4):192–195.
- Clopidogrel**  
Meier-Ewert HK, Nesto RW. Targeting the use of glycoprotein IIb/IIIa antagonists—the diabetic patient. 3(suppl 1):S20–S27.
- COAST**  
Best of the ACC Scientific Session 2002 [Meeting Review]. 3(2):85–104.
- Community-based practice**  
Gattis WA, O'Connor CM, Gheorghiadu M. Initiation management predischARGE process for assessment of carvedilol therapy for heart failure (IMPACT-HF) study: design and implications. 3(suppl 3):S48–S54.
- Computed tomography**  
Best of the AHA Scientific Sessions 2001 [Meeting Review]. 3(1):22–48.  
Nieman K, van Geuns R-JM, Wielopolski P, et al. Noninvasive coronary imaging in the new millennium: a comparison of computed tomography and magnetic resonance techniques. 3(2):77–84.
- Congestive heart failure**  
Aghababian RV. Acutely decompensated heart failure: opportunities to improve care and outcomes in the emergency department. 3(suppl 4):S3–S9.  
Best of the ACC Scientific Session 2002 [Meeting Review]. 3(2):85–104.  
Cesario DA, Fonarow GC. Beta-blocker therapy for heart failure: the standard of care. 3(1):14–21.  
Emmerman CL. Safety and efficacy of nesiritide for the treatment of decompensated heart failure. 3(suppl 4):S28–S34.
- Lepor NE. Doppler imaging to predict beta-blocker performance [Literature Review]. 3(4):206–207.
- Maisel A. B-type natriuretic peptide measurements in diagnosing congestive heart failure in the dyspneic emergency department patient. 3(suppl 4):S10–S17.
- Panacek EA. Role of noninvasive ventilation in the management of acutely decompensated heart failure. 3(suppl 4):S35–S40.
- Prystowsky EN. Cardiac resynchronization therapy for congestive heart failure [Literature Review]. 3(3):165–166.
- Weber MA. The angiotensin II receptor blockers: opportunities across the spectrum of cardiovascular disease. 3(4):183–191.
- Connective tissue disorder**  
Kumar K, Lepor NE, Naqvi TZ. Unusual presentation of an acute inferior myocardial infarction. 3(3):152–156.
- Continuous quality improvement**  
Young JB. Hospital-based systems to improve quality of care for heart-failure patients. 3(suppl 3):S36–S41.
- Coronary anomaly**  
Mixon TA, Watson LE. Single coronary artery with an ectopic origin and interarterial course: a case report and review of the literature. 3(2):107–110.
- Coronary artery**  
Kumar K, Lepor NE, Naqvi TZ. Unusual presentation of an acute inferior myocardial infarction. 3(3):152–156.  
Schwartz RS, Henry TD. Pathophysiology of coronary artery restenosis. 3(suppl 5):S4–S9.
- Coronary artery calcium scoring**  
Thomson LEJ, Hachamovitch R. Coronary artery calcium scoring using electron-beam computed tomography: where does this test fit into a clinical practice? 3(3):121–128.
- Coronary artery disease**  
Lepor NE. Prevention with statin and niacin [Literature Review]. 3(4):205–206.  
Meier-Ewert HK, Nesto RW. Targeting the use of glycoprotein IIb/IIIa antagonists—the diabetic patient. 3(suppl 1):S20–S27.  
Nesto RW. Stress perfusion nuclear imaging in diabetes [Literature Review]. 3(3):164–165.  
Nieman K, van Geuns R-JM, Wielopolski P, et al. Noninvasive coronary imaging in the new millennium: a comparison of computed tomography and magnetic resonance techniques. 3(2):77–84.  
Thomson LEJ, Hachamovitch R. Coronary artery calcium scoring using electron-beam computed tomography: where does this test fit into a clinical practice? 3(3):121–128.
- artery calcium scoring using electron-beam computed tomography: where does this test fit into a clinical practice? 3(3):121–128.
- Coronary artery disease, unprotected left main**  
Fasseas P, Holmes DR. Unprotected left main percutaneous coronary intervention [Literature Review]. 3(3):157–160.
- Coronary heart disease**  
Fonarow GC. Role of in-hospital initiation of cardioprotective therapies to improve treatment rates and clinical outcomes. 3(suppl 3):S2–S10.
- Coronary revascularization**  
Lepor NE, Madyoon H, Kereiakes D. Effective and efficient strategies for coronary revascularization in the drug-eluting stent era. 3(suppl 5):S38–S50.
- Coronary stenting**  
French MH, Faxon DP. Update on radiation for restenosis. 3(1):1–6.
- Coronary stents**  
McClellan DR, Eigler NL. Stent design: implications for restenosis. 3(suppl 5):S16–S22.
- Cost-effectiveness**  
Gilbert EM. Cost-effectiveness of beta-blocker treatment in heart failure. 3(suppl 3):S42–S47.
- Cost-effectiveness analysis**  
Dippel EJ. Practical issues of platelet glycoprotein IIb/IIIa receptor inhibition: saving lives and saving money. 3(suppl 1):S28–S34.
- C-reactive protein**  
Herrington DM, Potvin Klein K. Effects of estrogen on thrombosis and inflammation. [Meeting Review]. 3(1):49–56.
- DANAMI-2**  
Best of the ACC Scientific Session 2002 [Meeting Review]. 3(2):85–104.
- D-dimer**  
Herrington DM, Potvin Klein K. Effects of estrogen on thrombosis and inflammation. [Meeting Review]. 3(1):49–56.
- Death, sudden**  
Mixon TA, Watson LE. Single coronary artery with an ectopic origin and interarterial course: a case report and review of the literature. 3(2):107–110.
- Decompensation**  
Emmerman CL. Safety and efficacy of nesiritide for the treatment of decompensated heart failure. 3(suppl 4):S28–S34.
- Diabetes**  
Best of the AHA Scientific Sessions 2001 [Meeting Review]. 3(1):22–48.  
Faxon DP. Revascularization in diabetes: have stents made a difference? [Literature Review]. 3(1):60–62.

- Nesto RW. Stress perfusion nuclear imaging in diabetes [Literature Review]. 3(3):164–165.
- Diabetes mellitus**  
Meier-Ewert HK, Nesto RW. Targeting the use of glycoprotein IIb/IIIa antagonists—the diabetic patient. 3(suppl 1):S20–S27.
- Diabetic nephropathy**  
Weber MA. The angiotensin II receptor blockers: opportunities across the spectrum of cardiovascular disease. 3(4):183–191.
- Doppler**  
Pandian NG. Doppler hemodynamics. 3(1):57–59.
- Drug-eluting stent**  
Lepor NE, Madyoon H, Kereiakes D. Effective and efficient strategies for coronary revascularization in the drug-eluting stent era. 3(suppl 5):S38–S50.
- Dyslipidemias, mixed**  
Lepor NE. Triglycerides and coronary atherosclerosis: implications for treatment of mixed dyslipidemias [Literature Review]. 3(1):63–66.
- Dyspnea**  
Maisel A. B-type natriuretic peptide measurements in diagnosing congestive heart failure in the dyspneic emergency department patient. 3(suppl 4):S10–S17.
- E2F decoy**  
Best of the AHA Scientific Sessions 2001 [Meeting Review]. 3(1):22–48.
- Echocardiography**  
Best of the AHA Scientific Sessions 2001 [Meeting Review]. 3(1):22–48.  
Weyman AE. Assessing the performance of hand-carried echocardiographic devices [Literature Review]. 3(2):116–117.
- Edge effect**  
Waksman R. Vascular brachytherapy: applications in the era of drug-eluting stents. 3(suppl 5):S23–S30.
- Elderly**  
Yancy CW. Special clinical considerations of beta-blocker treatment. 3(suppl 3):S27–S35.
- Electron-beam computed tomography**  
Thomson LEJ, Hachamovitch R. Coronary artery calcium scoring using electron-beam computed tomography: where does this test fit into a clinical practice? 3(3):121–128.
- Emergency department**  
Aghababian RV. Acutely decompensated heart failure: opportunities to improve care and outcomes in the emergency department. 3(suppl 4):S3–S9.  
Fonarow GC. Pharmacologic therapies for acutely decompensated heart failure. 3(suppl 4):S18–S27.
- ENABLE**  
Best of the ACC Scientific Session 2002 [Meeting Review]. 3(2):85–104.
- Enalapril**  
Best of the ACC Scientific Session 2002 [Meeting Review]. 3(2):85–104.
- End-stage renal disease**  
McCullough PA. Cardiorenal risk: an important clinical intersection. 3(2):71–76.  
McCullough PA. Update from the International Society on Hypertension in Blacks [Meeting Review]. 3(4):192–195.
- Endothelial receptor antagonists**  
Best of the ACC Scientific Session 2002 [Meeting Review]. 3(2):85–104.
- Endotracheal intubation**  
Panacek EA, Kirk JD. Role of noninvasive ventilation in the management of acutely decompensated heart failure. 3(suppl 4):S35–S40.
- Enoxaparin**  
Best of the ACC Scientific Session 2002 [Meeting Review]. 3(2):85–104.
- Eplerenone**  
Best of the ACC Scientific Session 2002 [Meeting Review]. 3(2):85–104.
- Eptifibatide**  
Best of the ACC Scientific Session 2002 [Meeting Review]. 3(2):85–104.  
Lepor NE. Use of glycoprotein IIb/IIIa receptor inhibitors in acute coronary syndromes. 3(suppl 1):S3–S12.
- Evidence-based data**  
Young JB. Hospital-based systems to improve quality of care for heart-failure patients. 3(suppl 3):S36–S41.
- Evidence-based medicine**  
Gattis WA, O'Connor CM, Gheorghiade M. Initiation management predischARGE process for assessment of carvedilol therapy for heart failure (IMPACT-HF) study: design and implications. 3(suppl 3):S48–S54.
- Ezetimibe**  
Best of the AHA Scientific Sessions 2001 [Meeting Review]. 3(1):22–48.
- Fibrinogen**  
Herrington DM, Potvin Klein K. Effects of estrogen on thrombosis and inflammation. [Meeting Review]. 3(1):49–56.
- Fibrinolysis**  
Best of the ACC Scientific Session 2002 [Meeting Review]. 3(2):85–104.  
Lincoff AM. Targeting the use of platelet IIb/IIIa inhibitors: treatment of acute myocardial infarction. 3(suppl 1):S13–S19.
- Fibroblast growth factors**  
Grossman JD, Grossman W. Angiogenesis. 3(3):138–144.
- First in Man trial**  
Best of the ACC Scientific Session 2002 [Meeting Review]. 3(2):85–104.
- Flow velocity**  
Pandian NG. Doppler hemodynamics. 3(1):57–59.
- Gemfibrozil**  
Price MJ, Shah PK. New strategies in managing and preventing atherosclerosis: focus on HDL. 3(3):129–137.
- Gene therapy**  
Best of the AHA Scientific Sessions 2001 [Meeting Review]. 3(1):22–48.  
Grossman JD, Grossman W. Angiogenesis. 3(3):138–144.
- Gene transfer**  
Grossman JD, Grossman W. Angiogenesis. 3(3):138–144.
- Glycoprotein IIb/IIIa antagonists**  
Dippel EJ. Practical issues of platelet glycoprotein IIb/IIIa receptor inhibition: saving lives and saving money. 3(suppl 1):S28–S34.
- Glycoprotein IIb/IIIa receptor**  
Lincoff AM. Targeting the use of platelet IIb/IIIa inhibitors: treatment of acute myocardial infarction. 3(suppl 1):S13–S19.  
Meier-Ewert HK, Nesto RW. Targeting the use of glycoprotein IIb/IIIa antagonists—the diabetic patient. 3(suppl 1):S20–S27.
- Glycoprotein IIb/IIIa receptor inhibitors**  
Lepor NE. Use of glycoprotein IIb/IIIa receptor inhibitors in acute coronary syndromes. 3(suppl 1):S3–S12.  
Orford JL, Holmes DR. Abciximab readministration. 3(2):67–70.
- Heart failure**  
Best of the AHA Scientific Sessions 2001 [Meeting Review]. 3(1):22–48.  
Fonarow GC. Angiotensin receptor antagonist therapy fails to reduce heart failure mortality [Literature Review]. 3(3):162–163.  
Fonarow GC. Role of in-hospital initiation of cardioprotective therapies to improve treatment rates and clinical outcomes. 3(suppl 3):S2–S10.  
Fowler M. Beta-adrenergic blocking drugs in severe heart failure. 3(suppl 3):S20–S26.  
Gattis WA, O'Connor CM, Gheorghiade M. Initiation management predischARGE process for assessment of carvedilol therapy for heart failure (IMPACT-HF) study: design and implications. 3(suppl 3):S48–S54.  
Gheorghiade M, Gattis WA, O'Connor CM. Treatment gaps in the pharmacologic management of heart failure. 3(suppl 3):S11–S19.

- Gilbert EM. Cost-effectiveness of beta-blocker treatment in heart failure. 3(suppl 3):S42–S47.
- McCullough PA. Cardiorenal risk: an important clinical intersection. 3(2):71–76.
- Peacock WF. Rapid optimization: strategies for optimal care of decompensated congestive heart-failure patients in the emergency department. 3(suppl 4):S41–S48.
- Yancy CW. Special clinical considerations of beta-blocker treatment. 3(suppl 3):S27–S35.
- Young JB. Hospital-based systems to improve quality of care for heart-failure patients. 3(suppl 3):S36–S41.
- Heart failure, acute**  
Fonarow GC. Pharmacologic therapies for acutely decompensated heart failure. 3(suppl 4):S18–S27.
- Hemodynamics**  
Fonarow GC. Pharmacologic therapies for acutely decompensated heart failure. 3(suppl 4):S18–S27.
- Heparin**  
French MH, Faxon DP. Current anticoagulation options in percutaneous intervention: designing patient-specific strategies. 3(4):176–182.
- Meier-Ewert HK, Nesto RW. Targeting the use of glycoprotein IIb/IIIa antagonists—the diabetic patient. 3(suppl 1):S20–S27.
- Heparin, low molecular weight**  
French MH, Faxon DP. Current anticoagulation options in percutaneous intervention: designing patient-specific strategies. 3(4):176–182.
- High-density lipoprotein**  
Price MJ, Shah PK. New strategies in managing and preventing atherosclerosis: focus on HDL. 3(3):129–137.
- High-density lipoprotein cholesterol**  
Vogel RA. Alcohol, heart disease, and mortality: a review. 3(1):7–13.
- Hormone replacement therapy**  
Herrington DM, Potvin Klein K. Effects of estrogen on thrombosis and inflammation. [Meeting Review]. 3(1):49–56.
- Hyperlipidemia**  
Weyman AE. Exploring the relationship between hyperlipidemia and aortic stenosis [Literature Review]. 3(3):160–161.
- Hypertension**  
Best of the ACC Scientific Session 2002 [Meeting Review]. 3(2):85–104.
- Best of the AHA Scientific Sessions 2001 [Meeting Review]. 3(1):22–48.
- Lepor NE. Risk associated with “normal” blood pressure [Literature Review]. 3(3):161–162.
- McCullough PA. Update from the International Society on Hypertension in Blacks [Meeting Review]. 3(4):192–195.
- Weber MA. The angiotensin II receptor blockers: opportunities across the spectrum of cardiovascular disease. 3(4):183–191.
- Hypotension**  
Emerman CL. Safety and efficacy of nesiritide for the treatment of decompensated heart failure. 3(suppl 4):S28–S34.
- ICDs**  
Best of the ACC Scientific Session 2002 [Meeting Review]. 3(2):85–104.
- Imaging, noninvasive**  
Nieman K, van Geuns R-JM, Wielopolski P, et al. Noninvasive coronary imaging in the new millennium: a comparison of computed tomography and magnetic resonance techniques. 3(2):77–84.
- IMPACT-HF trial**  
Gattis WA, O'Connor CM, Gheorghiade M. Initiation management predischARGE process for assessment of carvedilol therapy for heart failure (IMPACT-HF) study: design and implications. 3(suppl 3):S48–S54.
- In-stent restenosis**  
French MH, Faxon DP. Update on radiation for restenosis. 3(1):1–6.
- Integrin**  
Dippel EJ. Practical issues of platelet glycoprotein IIb/IIIa receptor inhibition: saving lives and saving money. 3(suppl 1):S28–S34.
- INTERACT**  
Best of the ACC Scientific Session 2002 [Meeting Review]. 3(2):85–104.
- Intermittent claudication**  
Best of the AHA Scientific Sessions 2001 [Meeting Review]. 3(1):22–48.
- Interventional cardiology**  
Fasseas P, Holmes DR. Unprotected left main percutaneous coronary intervention [Literature Review]. 3(3):157–160.
- Intracoronary device**  
Best of the ACC Scientific Session 2002 [Meeting Review]. 3(2):85–104.
- Intracoronary radiation therapy**  
Lepor NE, Madyoon H, Kereiakes D. Effective and efficient strategies for coronary revascularization in the drug-eluting stent era. 3(suppl 5):S38–S50.
- Intravascular radiation**  
French MH, Faxon DP. Update on radiation for restenosis. 3(1):1–6.
- ISAR-STEREO**  
Best of the ACC Scientific Session 2002 [Meeting Review]. 3(2):85–104.
- Ischemia**  
Mixon TA, Watson LE. Single coronary artery with an ectopic origin and interarterial course: a case report and review of the literature. 3(2):107–110.
- Lamifiban**  
Lepor NE. Use of glycoprotein IIb/IIIa receptor inhibitors in acute coronary syndromes. 3(suppl 1):S3–S12.
- Left ventricular assist device**  
Best of the AHA Scientific Sessions 2001 [Meeting Review]. 3(1):22–48.
- Left ventricular dysfunction**  
Gheorghiade M, Gattis WA, O'Connor CM. Treatment gaps in the pharmacologic management of heart failure. 3(suppl 3):S11–S19.
- Left ventricular hypertrophy**  
Best of the ACC Scientific Session 2002 [Meeting Review]. 3(2):85–104.
- LIFE**  
Best of the ACC Scientific Session 2002 [Meeting Review]. 3(2):85–104.
- Lipid disorders**  
Lepor NE. Antioxidants as adjuvant therapy for cardiovascular disease [Literature Review]. 3(2):117–119.
- Lipid-lowering therapy**  
Fonarow GC. Role of in-hospital initiation of cardioprotective therapies to improve treatment rates and clinical outcomes. 3(suppl 3):S2–S10.
- LIPS**  
Best of the ACC Scientific Session 2002 [Meeting Review]. 3(2):85–104.
- Local drug delivery**  
Drachman DE. Clinical experience with drug-eluting stents. 3(suppl 5):S31–S37.
- Losartan**  
Best of the ACC Scientific Session 2002 [Meeting Review]. 3(2):85–104.
- MADIT II**  
Best of the ACC Scientific Session 2002 [Meeting Review]. 3(2):85–104.
- Magnetic resonance imaging**  
Best of the AHA Scientific Sessions 2001 [Meeting Review]. 3(1):22–48.
- Nieman K, van Geuns R-JM, Wielopolski P, et al. Noninvasive coronary imaging in the new millennium: a comparison of computed tomography and magnetic resonance techniques. 3(2):77–84.
- Microalbuminuria**  
McCullough PA. Cardiorenal risk: an important clinical intersection. 3(2):71–76.
- McCullough PA. Update from the International Society on Hypertension in Blacks [Meeting Review]. 3(4):192–195.
- Mitral stenosis**  
Scott NS, Weyman AE. Mitral valve replace-

- ment for restenosis after repeat percutaneous mitral valvuloplasty. 3(3):148–151.
- Mitral valve prolapse**  
Kumar K, Lepor NE, Naqvi TZ. Unusual presentation of an acute inferior myocardial infarction. 3(3):152–156.
- Mortality**  
Vogel RA. Alcohol, heart disease, and mortality: a review. 3(1):7–13.
- Myocardial infarction**  
Best of the AHA Scientific Sessions 2001 [Meeting Review]. 3(1):22–48.  
Faxon DP. Late-breaking trial results presented in Stockholm [Meeting Review]. 3(2):105–106.  
Fonarow GC. Role of in-hospital initiation of cardioprotective therapies to improve treatment rates and clinical outcomes. 3(suppl 3):S2–S10.  
Herrington DM, Potvin Klein K. Effects of estrogen on thrombosis and inflammation. [Meeting Review]. 3(1):49–56.  
Kumar K, Lepor NE, Naqvi TZ. Unusual presentation of an acute inferior myocardial infarction. 3(3):152–156.  
Lincoff AM. Targeting the use of platelet IIb/IIIa inhibitors: treatment of acute myocardial infarction. 3(suppl 1):S13–S19.  
McCullough PA. Cardiorenal risk: an important clinical intersection. 3(2):71–76.
- Myocardial infarction, acute**  
Best of the ACC Scientific Session 2002 [Meeting Review]. 3(2):85–104.  
Gersh BJ. Results of the ASSENT-3 trial [Literature Review]. 3(2):111–115.
- Natriuretic peptides**  
Aghababian RV. Acutely decompensated heart failure: opportunities to improve care and outcomes in the emergency department. 3(suppl 4):S3–S9.  
Maisel A. B-type natriuretic peptide measurements in diagnosing congestive heart failure in the dyspneic emergency department patient. 3(suppl 4):S10–S17.
- Neointima**  
Schwartz RS, Henry TD. Pathophysiology of coronary artery restenosis. 3(suppl 5):S4–S9.
- Nesiritide**  
Emerman CL. Safety and efficacy of nesiritide for the treatment of decompensated heart failure. 3(suppl 4):S28–S34.  
Peacock WF. Rapid optimization: strategies for optimal care of decompensated congestive heart-failure patients in the emergency department. 3(suppl 4):S41–S48.
- Neurohumoral activation**  
Cesario DA, Fonarow GC. Beta-blocker therapy for heart failure: the standard of care. 3(1):14–21.
- Niacin**  
Lepor NE. Prevention with statin and niacin [Literature Review]. 3(4):205–206.
- Nicorandil**  
Gersh BJ. Randomized trials of treatment for chronic stable angina [Meeting Review]. 3(3):145–147.
- Nitrates**  
Yeung AC. Folate treatment to prevent nitrate tolerance [Literature Review]. 3(1):62–63.
- Nitroglycerin**  
Gersh BJ. Randomized trials of treatment for chronic stable angina [Meeting Review]. 3(3):145–147.  
Peacock WF. Rapid optimization: strategies for optimal care of decompensated congestive heart-failure patients in the emergency department. 3(suppl 4):S41–S48.
- Noninvasive ventilation**  
Panacek EA, Kirk JD. Role of noninvasive ventilation in the management of acutely decompensated heart failure. 3(suppl 4):S35–S40.
- Nonselective beta/alpha-blockers**  
Cesario DA, Fonarow GC. Beta-blocker therapy for heart failure: the standard of care. 3(1):14–21.
- Norepinephrine**  
Fowler M. Beta-adrenergic blocking drugs in severe heart failure. 3(suppl 3):S20–S26.
- OVERTURE**  
Best of the ACC Scientific Session 2002 [Meeting Review]. 3(2):85–104.
- Pacing**  
Prystowsky EN. Cardiac resynchronization therapy for congestive heart failure [Literature Review]. 3(3):165–166.
- Paclitaxel**  
Best of the ACC Scientific Session 2002 [Meeting Review]. 3(2):85–104.  
Drachman DE. Clinical experience with drug-eluting stents. 3(suppl 5):S31–S37.
- Patent foramen ovale**  
Best of the ACC Scientific Session 2002 [Meeting Review]. 3(2):85–104.
- Percutaneous coronary intervention**  
Best of the ACC Scientific Session 2002 [Meeting Review]. 3(2):85–104.  
Dippel EJ. Practical issues of platelet glycoprotein IIb/IIIa receptor inhibition: saving lives and saving money. 3(suppl 1):S28–S34.  
Fasseas P, Holmes DR. Unprotected left main percutaneous coronary intervention [Literature Review]. 3(3):157–160.  
French MH, Faxon DP. Current anticoagulation options in percutaneous intervention: designing patient-specific strategies. 3(4):176–182.
- Orford JL, Holmes DR. Abciximab readministration. 3(2):67–70.
- Waksman R. Vascular brachytherapy: applications in the era of drug-eluting stents. 3(suppl 5):S23–S30.
- Percutaneous mitral valvuloplasty**  
Scott NS, Weyman AE. Mitral valve replacement for restenosis after repeat percutaneous mitral valvuloplasty. 3(3):148–151.
- Peripheral arterial disease**  
Best of the AHA Scientific Sessions 2001 [Meeting Review]. 3(1):22–48.
- Peripheral vascular disease**  
Ansel GM, George BS, Botti CF, Silver MJ. Use of glycoprotein IIb/IIIa platelet inhibitors in peripheral vascular interventions. 3(suppl 1):S35–S40.
- Plaque**  
Price MJ, Shah PK. New strategies in managing and preventing atherosclerosis: focus on HDL. 3(3):129–137.
- Plasmin-antiplasmin complex**  
Herrington DM, Potvin Klein K. Effects of estrogen on thrombosis and inflammation. [Meeting Review]. 3(1):49–56.
- Platelets**  
Lincoff AM. Targeting the use of platelet IIb/IIIa inhibitors: treatment of acute myocardial infarction. 3(suppl 1):S13–S19.
- Polymer**  
Drachman DE. Clinical experience with drug-eluting stents. 3(suppl 5):S31–S37.  
Rogers CDK. Drug-eluting stents: role of stent design, delivery vehicle, and drug selection. 3(suppl 5):S10–S15.
- Positive airway pressure, bi-level**  
Panacek EA, Kirk JD. Role of noninvasive ventilation in the management of acutely decompensated heart failure. 3(suppl 4):S35–S40.
- Positive airway pressure, continuous**  
Panacek EA, Kirk JD. Role of noninvasive ventilation in the management of acutely decompensated heart failure. 3(suppl 4):S35–S40.
- Positron emission tomography**  
Best of the AHA Scientific Sessions 2001 [Meeting Review]. 3(1):22–48.
- Pseudoaneurysm**  
Kumar K, Lepor NE, Naqvi TZ. Unusual presentation of an acute inferior myocardial infarction. 3(3):152–156.
- Pulmonary edema**  
Panacek EA, Kirk JD. Role of noninvasive ventilation in the management of acutely decompensated heart failure. 3(suppl 4):S35–S40.

**Pulmonary vein isolation**

Keane D, Ruskin J. Pulmonary vein isolation for atrial fibrillation. 3(4):167-175.

**Ranolazine**

Gersh BJ. Randomized trials of treatment for chronic stable angina [Meeting Review]. 3(3):145-147.

**Rapamycin**

Faxon DP. Late-breaking trial results presented in Stockholm [Meeting Review]. 3(2):105-106.

**RAVEL**

Best of the ACC Scientific Session 2002 [Meeting Review]. 3(2):85-104.

**Reinfarction**

Faxon DP. Late-breaking trial results presented in Stockholm [Meeting Review]. 3(2):105-106.

**Renal disease, end-stage**

Best of the AHA Scientific Sessions 2001 [Meeting Review]. 3(1):22-48.

**Renal infarction**

Safley DM, McCullough PA. Anti-phospholipid syndrome with renal artery embolism: case report. 3(4):196-201.

**Reperfusion**

Best of the ACC Scientific Session 2002 [Meeting Review]. 3(2):85-104.

Lincoff AM. Targeting the use of platelet IIb/IIIa inhibitors: treatment of acute myocardial infarction. 3(suppl 1):S13-S19.

**Restenosis**

Best of the AHA Scientific Sessions 2001 [Meeting Review]. 3(1):22-48.

Drachman DE. Clinical experience with drug-eluting stents. 3(suppl 5):S31-S37.

Faxon DP. Late-breaking trial results presented in Stockholm [Meeting Review]. 3(2):105-106.

French MH, Faxon DP. Update on radiation for restenosis. 3(1):1-6.

Lepor NE, Madyoon H, Kereiakes D. Effective and efficient strategies for coronary revascularization in the drug-eluting stent era. 3(suppl 5):S38-S50.

McClellan DR, Eigler NL. Stent design: implications for restenosis. 3(suppl 5):S16-S22.

Rogers CDK. Drug-eluting stents: role of stent design, delivery vehicle, and drug selection. 3(suppl 5):S10-S15.

Schwartz RS, Henry TD. Pathophysiology of coronary artery restenosis. 3(suppl 5):S4-S9.

Scott NS, Weyman AE. Mitral valve replacement for restenosis after repeat percutaneous mitral valvuloplasty. 3(3):148-151.

Waksman R. Vascular brachytherapy: applications in the era of drug-eluting stents. 3(suppl 5):S23-S30.

**Revascularization**

Faxon DP. Revascularization in diabetes: have stents made a difference? [Literature Review]. 3(1):60-62.

**Safety**

Emerman CL. Safety and efficacy of nesiritide for the treatment of decompensated heart failure. 3(suppl 4):S28-S34.

**Single-proton emission computed tomography**

Nesto RW. Stress perfusion nuclear imaging in diabetes [Literature Review]. 3(3):164-165.

Thomson LEJ, Hachamovitch R. Coronary artery calcium scoring using electron-beam computed tomography: where does this test fit into a clinical practice? 3(3):121-128.

**Sirolimus**

Best of the ACC Scientific Session 2002 [Meeting Review]. 3(2):85-104.

Drachman DE. Clinical experience with drug-eluting stents. 3(suppl 5):S31-S37.

**Special populations**

Yancy CW. Special clinical considerations of beta-blocker treatment. 3(suppl 3):S27-S35.

**Statins**

Best of the ACC Scientific Session 2002 [Meeting Review]. 3(2):85-104.

Lepor NE. Prevention with statin and niacin [Literature Review]. 3(4):205-206.

**Statin therapy**

Best of the AHA Scientific Sessions 2001 [Meeting Review]. 3(1):22-48.

**Stent**

Best of the ACC Scientific Session 2002 [Meeting Review]. 3(2):85-104.

Dippel EJ. Practical issues of platelet glycoprotein IIb/IIIa receptor inhibition: saving lives and saving money. 3(suppl 1):S28-S34.

Drachman DE. Clinical experience with drug-eluting stents. 3(suppl 5):S31-S37.

Faxon DP. Revascularization in diabetes: have stents made a difference? [Literature Review]. 3(1):60-62.

Schwartz RS, Henry TD. Pathophysiology of coronary artery restenosis. 3(suppl 5):S4-S9.

**Stent design**

McClellan DR, Eigler NL. Stent design: implications for restenosis. 3(suppl 5):S16-S22.

**Stroke**

Best of the ACC Scientific Session 2002 [Meeting Review]. 3(2):85-104.

Lepor NE. Choices for stroke prevention [Literature Review]. 3(4):202-203.

**Sympathetic nervous system**

Fowler M. Beta-adrenergic blocking drugs in severe heart failure. 3(suppl 3):S20-S26.

**Sympathetic nervous system activation**

Cesario DA, Fonarow GC. Beta-blocker therapy for heart failure: the standard of care. 3(1):14-21.

**Systolic dysfunction**

Aghababian RV. Acutely decompensated heart failure: opportunities to improve care and outcomes in the emergency department. 3(suppl 4):S3-S9.

**Tacrolimus**

Best of the ACC Scientific Session 2002 [Meeting Review]. 3(2):85-104.

**Tezosentan**

Best of the AHA Scientific Sessions 2001 [Meeting Review]. 3(1):22-48.

**Thrombin inhibitors**

French MH, Faxon DP. Current anticoagulation options in percutaneous intervention: designing patient-specific strategies. 3(4):176-182.

**Thrombocytopenia**

Orford JL, Holmes DR. Abciximab readministration. 3(2):67-70.

**Thrombosis**

Waksman R. Vascular brachytherapy: applications in the era of drug-eluting stents. 3(suppl 5):S23-S30.

**Thrombosis, abnormal**

Safley DM, McCullough PA. Anti-phospholipid syndrome with renal artery embolism: case report. 3(4):196-201.

**Thrombus**

Meier-Ewert HK, Nesto RW. Targeting the use of glycoprotein IIb/IIIa antagonists—the diabetic patient. 3(suppl 1):S20-S27.

Schwartz RS, Henry TD. Pathophysiology of coronary artery restenosis. 3(suppl 5):S4-S9.

Waksman R. Vascular brachytherapy: applications in the era of drug-eluting stents. 3(suppl 5):S23-S30.

**Tirofiban**

Lepor NE. Use of glycoprotein IIb/IIIa receptor inhibitors in acute coronary syndromes. 3(suppl 1):S3-S12.

**Transforming growth factor**

Grossman JD, Grossman W. Angiogenesis. 3(3):138-144.

**Triglycerides**

Lepor NE. Triglycerides and coronary atherosclerosis: implications for treatment of mixed dyslipidemias [Literature Review]. 3(1):63-66.

**Valvular disease**

Safley DM, McCullough PA. Anti-phospholipid syndrome with renal artery embolism: case report. 3(4):196-201.

### **Vascular brachytherapy**

Waksman R. Vascular brachytherapy: applications in the era of drug-eluting stents. 3(suppl 5):S23–S30.

### **Vascular disease**

Rogers CDK. Drug-eluting stents: role of stent design, delivery vehicle, and drug selection. 3(suppl 5):S10–S15.

### **Vascular endothelial growth factor**

Best of the AHA Scientific Sessions 2001 [Meeting Review]. 3(1):22–48.

Grossman JD, Grossman W. Angiogenesis. 3(3):138–144.

### **Vascular inflammation**

Herrington DM, Potvin Klein K. Effects of estrogen on thrombosis and inflammation. [Meeting Review]. 3(1):49–56.

### **Vasodilators**

Fonarow GC. Pharmacologic therapies for acutely decompensated heart failure. 3(suppl 4):S18–S27.

### **Vasopeptidase inhibition**

Best of the ACC Scientific Session 2002 [Meeting Review]. 3(2):85–104.

### **Venous thrombosis**

Herrington DM, Potvin Klein K. Effects of

estrogen on thrombosis and inflammation. [Meeting Review]. 3(1):49–56.

### **Warfarin**

Faxon DP. Late-breaking trial results presented in Stockholm [Meeting Review]. 3(2):105–106.

### **WIZARD**

Best of the ACC Scientific Session 2002 [Meeting Review]. 3(2):85–104.

### **Women**

Yancy CW. Special clinical considerations of beta-blocker treatment. 3(suppl 3):S27–S35.